- Bristol Myers Squibb Canada announced updates to the BREYANZI (lisocabtagene maraleucel) product monograph, reducing the recommended proximity-to-treatment-centre requirement from 28 days to 14 days and driving restrictions from eight weeks to four weeks for eligible patients.
- The revised guidance is backed by safety data from seven clinical trials involving 691 patients and real-world registry data from 877 patients, showing that treatment-related adverse event risks decline significantly after the first 14 days post-infusion.
- The shortened monitoring period may reduce travel, logistical, emotional, and financial burdens on patients and caregivers while allowing appropriate patients to return to community-based care sooner.
- BREYANZI is a CD19-directed CAR T-cell therapy approved in Canada for certain adults with relapsed or refractory large B-cell lymphomas, including eligible second-line patients whose disease progresses within 12 months of first-line treatment.
Takeaways:
Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treated population and improve therapy uptake, especially for patients living far from major cancer centres. It also makes Breyanzi more competitive within the CAR T class in Canada, supports smoother centre throughput and bed planning, and may strengthen BMS’s position with payers and referrers by demonstrating robust real‑world safety that justifies a less resource-intensive monitoring model.
Source: CA Newswire
